5-benzylbenzofuran-2-ylboronic acid | 939050-20-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 5-benzylbenzofuran-2-ylboronic acid
• 英文别名: (5-benzyl-1-benzofuran-2-yl)boronic acid
• CAS: 939050-20-1
• 化学式: C₁₅H₁₃BO₃
• 分子量: 252.077
• InChiKey: ZVKRXGQTFJJWHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  53.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-benzylbenzofuran-2-ylboronic acid 在 bis-triphenylphosphine-palladium(II) chloride 、 sodium cyanoborohydride 、 溶剂黄146 、 三乙胺 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 为溶剂， 生成 1-((4-(5-benzylbenzofuran-2-yl)-3-fluorophenyl)methyl)azetidine-3-carboxylic acid
  参考文献：
  名称：

  Benzofuran Derivatives as Potent, Orally Active S1P₁ Receptor Agonists: A Preclinical Lead Molecule for MS

  摘要：

  We have discovered novel benzofuran-based S1P(1) agonists with excellent in vitro potency and selectivity. 1-((4-(5-Benzylbenzofuran-2-yl)-3-fluorophenyl)methyl) azetidine-3-carboxylic acid (18) is a potent S1P(1) agonist with > 1000 x selectivity over S1P(3). It demonstrated a good in vitro ADME profile and excellent oral bioavailability across species. Dosed orally at 0.3 mg/kg, 18 significantly reduced blood lymphocyte counts 24 h postdose and demonstrated efficacy in a mouse EAE model of relapsing MS.

  DOI：

  10.1021/ml100227q
• 作为产物：
  描述：

  4-羟基二苯甲烷 在 正丁基锂 、 硼酸三异丙酯 、 potassium hydroxide 作用下， 以 四氢呋喃 、 二甲基亚砜 、 苯 为溶剂， 反应 20.0h， 生成 5-benzylbenzofuran-2-ylboronic acid
  参考文献：
  名称：

  Benzofuran Derivatives as Potent, Orally Active S1P₁ Receptor Agonists: A Preclinical Lead Molecule for MS

  摘要：

  We have discovered novel benzofuran-based S1P(1) agonists with excellent in vitro potency and selectivity. 1-((4-(5-Benzylbenzofuran-2-yl)-3-fluorophenyl)methyl) azetidine-3-carboxylic acid (18) is a potent S1P(1) agonist with > 1000 x selectivity over S1P(3). It demonstrated a good in vitro ADME profile and excellent oral bioavailability across species. Dosed orally at 0.3 mg/kg, 18 significantly reduced blood lymphocyte counts 24 h postdose and demonstrated efficacy in a mouse EAE model of relapsing MS.

  DOI：

  10.1021/ml100227q

文献信息

• S1P receptor modulating compounds and use thereof
  申请人：Saha Ashis K.

  公开号：US20080064677A9

  公开（公告）日：2008-03-13

  The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behcet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.

  本发明涉及一般式（I）的化合物，其作为S1P受体调节剂具有活性，并使用这种化合物来治疗与不适当的S1P受体活性相关的疾病。这些化合物可以用作免疫调节剂，例如，用于治疗或预防自身免疫和相关免疫性疾病，包括全身性红斑狼疮、炎症性肠病（如克罗恩病和溃疡性结肠炎）、1型糖尿病、葡萄膜炎、牛皮癣、重症肌无力、类风湿性关节炎、非肾小球性肾病、肝炎、Behcet病、肾小球肾炎、慢性血小板减少性紫癜、溶血性贫血、肝炎和Wegner肉芽肿；以及用于治疗其他疾病。
• S1P Receptor Modulating Compounds and Use Thereof
  申请人：Saha Ashis K.

  公开号：US20110059945A1

  公开（公告）日：2011-03-10

  The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.

  本发明涉及一般式（I）的化合物，其具有作为S1P受体调节剂的活性，以及使用这些化合物治疗与不适当的S1P受体活性相关的疾病。这些化合物可用作免疫调节剂，例如，用于治疗或预防自身免疫和相关免疫性疾病，包括全身性红斑狼疮、克罗恩病和溃疡性结肠炎、I型糖尿病、葡萄膜炎、银屑病、重症肌无力、类风湿性关节炎、非肾小球性肾病、肝炎、Behçet病、肾小球肾炎、慢性血小板减少性紫癜、溶血性贫血、肝炎和Wegner肉芽肿；以及用于治疗其他疾病。
• WO2007/61458
  申请人：——

  公开号：——

  公开（公告）日：——
• 1,2,4-Triazolsulfone: A novel isosteric replacement of acylsulfonamides in the context of Na V 1.7 inhibition
  作者：Alessandro A. Boezio、Kristin Andrews、Christiane Boezio、Margaret Chu-Moyer、Katrina W. Copeland、Erin F. DiMauro、Robert S. Foti、Robert T. Fremeau、Hua Gao、Stephanie Geuns-Meyer、Russell F. Graceffa、Hakan Gunaydin、Hongbing Huang、Daniel S. La、Joseph Ligutti、Bryan D. Moyer、Emily A. Peterson、Violeta Yu、Matthew M. Weiss

  DOI：10.1016/j.bmcl.2018.04.035

  日期：2018.6

  Recently, the identification of several classes of aryl sulfonamides and acyl sulfonamides that potently inhibit Na(v)1.7 and demonstrate high levels of selectivity over other Na-v isoforms have been reported. The fully ionizable nature of these inhibitors has been shown to be an important part of the pharmacophore for the observed potency and isoform selectivity. The requirement of this functionality, however, has presented challenges associated with optimization toward inhibitors with drug-like properties and minimal off-target activity. In an effort to obviate these challenges, we set out to develop an orally bioavailable, selective Na(v)1.7 inhibitor, lacking these acidic functional groups. Herein, we report the discovery of a novel series of inhibitors wherein a triazolesulfone has been designed to serve as a bioisostere for the acyl sulfonamide. This work culminated in the delivery of a potent series of inhibitors which demonstrated good levels of selectivity over Na v 1.5 and favorable pharmacokinetics in rodents. (C) 2018 Elsevier Ltd. All rights reserved.
• Benzofuran Derivatives as Potent, Orally Active S1P₁ Receptor Agonists: A Preclinical Lead Molecule for MS
  作者：Ashis K. Saha、Xiang Yu、Jian Lin、Mercedes Lobera、Anurag Sharadendu、Srinivas Chereku、Nili Schutz、Dalia Segal、Yael Marantz、Dilara McCauley、Scot Middleton、Jerry Siu、Roland W. Bürli、Janet Buys、Michelle Horner、Kevin Salyers、Michael Schrag、Hugo M. Vargas、Yang Xu、Michele McElvain、Han Xu

  DOI：10.1021/ml100227q

  日期：2011.2.10

  We have discovered novel benzofuran-based S1P(1) agonists with excellent in vitro potency and selectivity. 1-((4-(5-Benzylbenzofuran-2-yl)-3-fluorophenyl)methyl) azetidine-3-carboxylic acid (18) is a potent S1P(1) agonist with > 1000 x selectivity over S1P(3). It demonstrated a good in vitro ADME profile and excellent oral bioavailability across species. Dosed orally at 0.3 mg/kg, 18 significantly reduced blood lymphocyte counts 24 h postdose and demonstrated efficacy in a mouse EAE model of relapsing MS.